Interleukin 15 levels in serum may predict a severe disease course in patients with early arthritis

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  González Álvaro, Isidoro ^a   Ortiz, Ana M ^a   Alvaro Gracia, José María ^a   Castañeda, Santos ^a   Díaz Sánchez, Belen ^a   Carvajal, Inmaculada ^b   García Vadillo, J Alberto ^a   Humbría, Alicia ^a   López Bote, J Pedro ^a   Patiño, Esther ^a   Tomero, Eva G ^a   Vicente, Esther F ^a   Sabando, Pedro ^a   García Vicuña, Rosario ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b Sanatorio Nuestra Senora del Rosario   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD SALT; INTERLEUKIN 15; LEFLUNOMIDE; METHOTREXATE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; IL15 PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; AGED; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE REGISTRY; DISEASE SEVERITY; EARLY ARTHRITIS; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRESCRIPTION; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; BLOOD; IMMUNOLOGY; MIDDLE AGED; ONSET AGE; PATHOLOGY; RISK FACTOR;

ADULT; AGE OF ONSET; ANTIRHEUMATIC AGENTS; ARTHRITIS; AUTOANTIBODIES; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-15; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; RISK FACTORS;

EID: 84855295463     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029492     Document Type: Article

References (41)

1. Allaart CF, Breedveld FC, Dijkmans BA, (2007) Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study. J Rheumatol Suppl 80 pp. 25-33.
2. Castro-Rueda H, Kavanaugh A, (2008) Biologic therapy for early rheumatoid arthritis: the latest evidence. Curr Opin Rheumatol 20: 314-319.
3. Emery P, Van Vollenhoven R, Ostergaard M, Choy E, Combe B, et al. (2009) Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe. Ann Rheum Dis 68: 456-459.
4. Schoels M, Knevel R, Aletaha D, Bijlsma JW, Breedveld FC, et al. (2010) Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 69: 638-643.
5. Tornero Molina J, Sanmartí Sala R, Rodriguez Valverde V, Martín Mola E, Marenco de la Fuente JL, et al. (2010) Actualización del Documento Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide. Reumatol Clin 6: 23-36.
6. de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, Schreuder GM, Ewals JA, et al. (2008) Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 58: 1293-1298.
7. Raza K, Filer A, (2009) Predicting the development of RA in patients with early undifferentiated arthritis. Best Pract Res Clin Rheumatol 23: 25-36.
8. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, Pineiro A, Garcia-Porrua C, et al. (2007) HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 57: 125-132.
9. Szodoray P, Szabo Z, Kapitany A, Gyetvai A, Lakos G, et al. (2010) Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev 9: 140-143.
10. Haupl T, Stuhlmuller B, Grutzkau A, Radbruch A, Burmester GR, (2010) Does gene expression analysis inform us in rheumatoid arthritis? Ann Rheum Dis 69 (Suppl 1): i37-42.
11. Smolen JS, Aletaha D, Grisar J, Redlich K, Steiner G, et al. (2008) The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now? Arthritis Res Ther 10: 208.
12. Gonzalez-Alvaro I, Dominguez-Jimenez C, Ortiz AM, Nunez-Gonzalez V, Roda-Navarro P, et al. (2006) Interleukin-15 and interferon-gamma participate in the cross-talk between natural killer and monocytic cells required for tumour necrosis factor production. Arthritis Res Ther 8: R88.
13. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY, (1997) Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med 3: 189-195.
14. Miranda-Carus ME, Balsa A, Benito-Miguel M, Perez de Ayala C, Martin-Mola E, (2004) IL-15 and the initiation of cell contact-dependent synovial fibroblast-T lymphocyte cross-talk in rheumatoid arthritis: effect of methotrexate. J Immunol 173: 1463-1476.
15. Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, et al. (2000) High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 164: 2832-2838.
16. Yoshihara K, Yamada H, Hori A, Yajima T, Kubo C, et al. (2007) IL-15 exacerbates collagen-induced arthritis with an enhanced CD4+ T cell response to produce IL-17. Eur J Immunol 37: 2744-2752.
17. Cho ML, Ju JH, Kim KW, Moon YM, Lee SY, et al. (2007) Cyclosporine A inhibits IL-15-induced IL-17 production in CD4+ T cells via down-regulation of PI3K/Akt and NF-kappaB. Immunol Lett 108: 88-96.
18. Gonzalez-Alvaro I, Ortiz Garcia AM, Dominguez-Jimenez C, Aragon-Bodi A, Diaz-Sanchez B, et al. (2009) Inhibition of TNF and IL-17 production by leflunomide involves the JAK/STAT pathway. Ann Rheum Dis 68: 1644-1650.
19. Neumann E, Gay S, Muller-Ladner U, (2005) The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models. Arthritis Rheum 52: 2960-2967.
20. Ogata Y, Kukita A, Kukita T, Komine M, Miyahara A, et al. (1999) A novel role of IL-15 in the development of osteoclasts: inability to replace its activity with IL-2. J Immunol 162: 2754-2760.
21. Schett G, Hayer S, Zwerina J, Redlich K, Smolen JS, (2005) Mechanisms of Disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol 1: 47-54.
22. Miranda-Carus ME, Benito-Miguel M, Balsa A, Cobo-Ibanez T, Perez de Ayala C, et al. (2006) Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. Arthritis Rheum 54: 1151-1164.
23. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, et al. (1994) Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 180: 1395-1403.
24. Liu CC, Perussia B, Young JD, (2000) The emerging role of IL-15 in NK-cell development. Immunol Today 21: 113-116.
25. Carroll HP, Paunovic V, Gadina M, (2008) Signalling, inflammation and arthritis: Crossed signals: the role of interleukin-15 and-18 in autoimmunity. Rheumatology (Oxford) 47: 1269-1277.
26. McInnes IB, al-Mughales J, Field M, Leung BP, Huang FP, et al. (1996) The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med 2: 175-182.
27. Ortiz AM, Laffon A, Gonzalez-Alvaro I, (2002) CD69 expression on lymphocytes and interleukin-15 levels in synovial fluids from different inflammatory arthropathies. Rheumatol Int 21: 182-188.
28. Thurkow EW, van der Heijden IM, Breedveld FC, Smeets TJ, Daha MR, et al. (1997) Increased expression of IL-15 in the synovium of patients with rheumatoid arthritis compared with patients with Yersinia-induced arthritis and osteoarthritis. J Pathol 181: 444-450.
29. Baslund B, Tvede N, Danneskiold-Samsoe B, Larsson P, Panayi G, et al. (2005) Targeting interleukin-15 in patients with rheumatoid arthritis: A proof-of-concept study. Arthritis Rheum 52: 2686-2692.
30. Ruchatz H, Leung BP, Wei XQ, McInnes IB, Liew FY, (1998) Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen- induced immunopathology. J Immunol 160: 5654-5660.
31. Cordero OJ, Salgado FJ, Mera-Varela A, Nogueira M, (2001) Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis. Rheumatol Int 21: 69-74.
32. Gonzalez-Alvaro I, Ortiz AM, Garcia-Vicuna R, Balsa A, Pascual-Salcedo D, et al. (2003) Increased serum levels of interleukin-15 in rheumatoid arthritis with long- term disease. Clin Exp Rheumatol 21: 639-642.
33. Suzuki J, Morimoto S, Amano H, Tokano Y, Takasaki Y, et al. (2001) Serum levels of interleukin 15 in patients with rheumatic diseases. J Rheumatol 28: 2389-2391.
34. Lamana A, Ortiz AM, Alvaro-Gracia JM, Diaz-Sanchez B, Novalbos J, et al. (2010) Characterization of serum interleukin-15 in healthy volunteers and patients with early arthritis to assess its potential use as a biomarker. Eur Cytokine Netw 21: 186-194.
35. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324.
36. Esteve-Vives J, Batlle-Gualda E, Reig A, (1993) Spanish version of the Health Assessment Questionnaire: reliability, validity and transcultural equivalency. Grupo para la Adaptacion del HAQ a la Poblacion Espanola. J Rheumatol 20: 2116-2122.
37. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, et al. (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38: 44-48.
38. Ibanez M, Ortiz AM, Castrejon I, Garcia-Vadillo JA, Carvajal I, et al. (2010) A rational use of glucocorticoids in patients with early arthritis has a minimal impact on bone mass. Arthritis Res Ther 12: R50.
39. Hardin J, Hilbe J, (2007) Generalized linear models and extensions College Station (Texas) Stata Press.
40. Pan W, (2001) Model selection in estimating equations. Biometrics 57: 529-534.
41. Rodríguez-Valverde V, Cáliz Cáliz R, Álvaro-Gracia Álvaro JM, Marenco de la Fuente JL, Mulero-Mendoza J, et al. (2006) III Actualización del Consenso de la Sociedad Española de Reumatología sobre terapia biológica en la artritis reumatoide. Reumatol Clin 2: S52-59.